Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Riluzole with or without lithium carbonate in amyotrophic lateral sclerosis
RBR-2n5mtqPhase 3Completed
- Sponsor
- Secretaria de Estado de Saúde do Distrito Federal
- Start
- Feb 2014
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in amyotrophic lateral sclerosis (ALS) comparing Riluzole + lithium carbonate with Riluzole alone (2 arms). Primary endpoints: Clinical follow-up and Electromyographic follow-up. Started Feb 2014; status: completed.
02
Drugs
riluzolelithium carbonate
03
Conditions
amyotrophic lateral sclerosis (ALS)
Beyond the preview
Go deeper on RBR-2n5mtq.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on RBR-2n5mtq.